Bicara Therapeutics opened lower at $10.40, compared with its previous close of $10.53. In the last trading session, the stock traded between $9.76 and $10.45. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Bicara Therapeutics is now worth
$ 43.21
Resulting in a loss of
$ 56.79 (56.79%)
Note: Past profits do not guarantee future returns.
Rating from 7 Analysts
Today's Change
$-0.41 (-3.93%)
Day High
$10.45
Day Low
$9.76
Day Open
$10.40
Prev Close
$10.53
Volume
15,07,260
1W Return
13.88%
1M Return
-41.67%
3M Return
-57.41%
6M Return
-55.86%
1Y Return
-31.32%
Market Cap ($ Mn)
672
PE Ratio
-
PB Ratio
3.29
PEG Ratio
-
ROE
-31.49%
ROCE
-35.48%
EPS (TTM)
-
1 Week
13.88%
1 Month
-41.67%
3 Months
-57.41%
6 Months
-55.86%
9 Months
-31.65%
HC Wainwright lowers Bicara Therapeutics price target to $36
HC Wainwright & Co. lowered Bicara Therapeutics' price target to $36 from $42. The brokerage maintained its Buy rating on the stock. Morgan Stanley previously cut the target to $30 from $41 while keeping an Overweight rating. Both firms continue to hold positive views on the company's long-term prospects.
YesterdayBicara Therapeutics Q3FY26 Results: R&D expenses rise 71% to $56.5 million
R&D expenses rose 71% YoY to $56.5 million in Q3FY26 due to pivotal trial costs. Cash reserves stand at $442.3 million, providing runway into first half of 2029. FORTIFY HN01 study achieved substantial enrollment; interim analysis expected mid-2027. G&A expenses increased 149% YoY to $19.2 million as commercial preparation accelerates. Phase 1b data shows 54% objective response rate and 22-month median duration of response.
3 days agoBicara Therapeutics to report Q3FY26 results on Nov 9
Bicara Therapeutics will report Q3 2026 results on November 9, 2026. Conference call scheduled for 8:30 am ET on the same day. Webcast replay available for 30 days post-event. Lead candidate ficerafusp alfa targets solid tumors.
10 days agoBTIG maintains Buy on Bicara Therapeutics, raises price target to $39
BTIG analyst Jeet Mukherjee maintains a Buy rating on Bicara Therapeutics (NASDAQ: BCAX). The firm raised its price target for the stock from $28 to $39, signaling increased valuation expectations for the biotechnology company.
3mo agoBicara Therapeutics Q2 EPS of $(0.82) beats estimates
Bicara Therapeutics Inc. announced Q2 2026 results with an EPS of $(0.82), beating the $(0.84) analyst estimate by 2.38%. Although losses widened by 64% from the previous year's $(0.50), the beat indicates better-than-expected performance relative to consensus forecasts.
3mo agoBicara Therapeutics grants stock options to four new employees
Bicara Therapeutics Inc. granted non-qualified stock options for 191,425 shares to four new employees on July 1, 2026, under its 2026 Inducement Plan. The options have an exercise price of $28.91 per share and vest over a four-year period. The awards were approved by the independent compensation committee pursuant to Nasdaq Listing Rule 5635(c)(4).
4mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Bicara Therapeutics is now worth
$ 43.21
Resulting in a loss of
$ 56.79 (56.79%)
Note: Past profits do not guarantee future returns.
